Glufosinate treatment in vitro, as low as 10 μM, recapitulates the effect of MSO on IL10 macrophages, leading to a metabolic reprogramming, associated with a HIF1α‐dependent M1‐like phenotype, that functionally translates into a decreased immune suppression, angiogenesis, and cancer cell invasion. The gene discussed is IL10; the disease is cancer.